2024
HIV, HIV-Specific Factors, and Myocardial Disease in Women
Kato Y, Ambale-Venkatesh B, Naveed M, Shitole S, Peng Q, Levsky J, Haramati L, Ordovas K, Noworolski S, Lee Y, Kim R, Lazar J, Anastos K, Tien P, Kaplan R, Lima J, Kizer J. HIV, HIV-Specific Factors, and Myocardial Disease in Women. Clinical Infectious Diseases 2024, 79: 451-461. PMID: 38356158, PMCID: PMC11327791, DOI: 10.1093/cid/ciae077.Peer-Reviewed Original ResearchCardiac magnetic resonanceHIV-specific factorsAntiretroviral therapyFibro-inflammationCardiac end-organ damageIncreased risk of cardiovascular diseasePersistent viral suppressionCardiovascular diseaseCD4+ lymphopeniaAssociation of HIVEnd-organ damageRisk of cardiovascular diseaseExtracellular volume fractionSan Francisco siteUnsuppressed viremiaViral suppressionHealthy volunteersMultivariate linear regressionMyocardial fibrosisMyocardial diseaseIncreased riskAdherence strategiesHIVHigher ECVLatent infection
2023
Mechanistic Implications of Cortical Superficial Siderosis in Patients With Mixed Location Intracerebral Hemorrhage and Cerebral Microbleeds
Das A, Gokcal E, Biffi A, Regenhardt R, Pasi M, Abramovitz Fouks A, Viswanathan A, Goldstein J, Schwamm L, Rosand J, Greenberg S, Gurol M. Mechanistic Implications of Cortical Superficial Siderosis in Patients With Mixed Location Intracerebral Hemorrhage and Cerebral Microbleeds. Neurology 2023, 101: e636-e644. PMID: 37290968, PMCID: PMC10424843, DOI: 10.1212/wnl.0000000000207476.Peer-Reviewed Original ResearchConceptsCortical superficial siderosisCerebral microbleedsSuperficial siderosisIntracerebral hemorrhageHypertensive end-organ damagePresence of CMBsCerebral small vessel diseaseAdjusted hazard ratioEnd-organ damageCoronary artery diseaseDeep cerebral microbleedsSmall vessel diseaseImaging-based classificationLogistic regression modelsICH survivorsProspective databaseHazard ratioReferral centerArtery diseaseConsecutive patientsVentricular hypertrophyVessel diseaseICH recurrenceWarrant confirmationICH riskSmooth Muscle Mineralocorticoid Receptor Promotes Hypertension After Preeclampsia
Biwer L, Lu Q, Ibarrola J, Stepanian A, Man J, Carvajal B, Camarda N, Zsengeller Z, Skurnik G, Seely E, Karumanchi S, Jaffe I. Smooth Muscle Mineralocorticoid Receptor Promotes Hypertension After Preeclampsia. Circulation Research 2023, 132: 674-689. PMID: 36815487, PMCID: PMC10119809, DOI: 10.1161/circresaha.122.321228.Peer-Reviewed Original ResearchConceptsBlood pressureSMC-MRHypertensive stimuliBP responseSmooth Muscle Cell Mineralocorticoid ReceptorsAngII type 1 receptorType 1 receptor expressionMR transcriptional activityIncreased cardiovascular riskElevated blood pressureEnd-organ damageHigh salt intakeHigh blood pressureRisk of hypertensionType 1 receptorSoluble VEGF receptorAngII infusionPrior preeclampsiaMR antagonismCardiovascular riskNormotensive pregnanciesSalt dietAortic stiffnessSalt intakeOrgan damage
2022
Acute kidney injury due to myoglobin cast nephropathy in the setting of coronavirus disease 2019-mediated rhabdomyolysis: a case report
Tuan J, Ogbuagu O, Kumar D, Altice F, Fikrig M. Acute kidney injury due to myoglobin cast nephropathy in the setting of coronavirus disease 2019-mediated rhabdomyolysis: a case report. Journal Of Medical Case Reports 2022, 16: 491. PMID: 36578087, PMCID: PMC9795945, DOI: 10.1186/s13256-022-03721-z.Peer-Reviewed Case Reports and Technical NotesConceptsAcute kidney injuryCoronavirus disease 2019Kidney injuryDisease 2019Cast nephropathyEnd-organ damageRenal biopsy findingsSpectrum of diseaseBaseline 6Gastrointestinal symptomsHospital courseBiopsy findingsCase presentationAPoor appetiteRenal failureRenal functionOral intakeUrine outputInitial diagnosisCaucasian manCase reportRhabdomyolysisNephropathyAbnormal tasteOrgan systemsEffect of intravenous antihypertensives on outcomes of severe hypertension in hospitalized patients without acute target organ damage
Ghazi L, Li F, Simonov M, Yamamoto Y, Nugent J, Greenberg J, Bakhoum C, Peixoto A, Wilson F. Effect of intravenous antihypertensives on outcomes of severe hypertension in hospitalized patients without acute target organ damage. Journal Of Hypertension 2022, 41: 288-294. PMID: 36583354, PMCID: PMC9799038, DOI: 10.1097/hjh.0000000000003328.Peer-Reviewed Original ResearchConceptsAcute target organ damageTarget organ damageSevere hypertensionOrgan damageIntravenous antihypertensivesBP elevationClinical outcomesMyocardial injuryTarget end-organ damageOverlap propensity scoreSevere BP elevationAcute kidney injuryBlood pressure reductionEnd-organ damageRisk of strokeInpatient hypertensionCardiovascular eventsIndex hospitalizationKidney injuryRetrospective studyHypertensionAntihypertensivesHospitalizationCox modelPatients
2020
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2020, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agentsCost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi P, Lee A. Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura. Blood 2020, 136: 18-19. DOI: 10.1182/blood-2020-138515.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraQuality-adjusted life yearsIntensive care unitTherapeutic plasma exchangeHERCULES trialCost-effectiveness analysisCaplacizumab treatmentRituximab useTITAN trialHospital lengthTPE sessionsThrombocytopenic purpuraTreatment armsAcquired Thrombotic Thrombocytopenic PurpuraLong-term disease courseThrombotic microangiopathy leadingEnd-organ damagePlatelet count recoveryLong-term followHealth system perspectiveOne-way sensitivity analysesPotential confounding factorsCost-effectiveness ratioLife-threatening diseaseWhat is the future of patient-reported outcomes in sickle-cell disease?
Singh S, Bakshi N, Mahajan P, Morris C. What is the future of patient-reported outcomes in sickle-cell disease? Expert Review Of Hematology 2020, 13: 1165-1173. PMID: 33034214, PMCID: PMC7722233, DOI: 10.1080/17474086.2020.1830370.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdultAnemia, Sickle CellChildClinical ProtocolsClinical Trials as TopicData AccuracyData CollectionDatabases, FactualDecision Making, SharedHumansInformation SystemsNational Institutes of Health (U.S.)Pain MeasurementPatient Reported Outcome MeasuresPatient-Centered CareQuality of LifeSelf ReportSeverity of Illness IndexUnited StatesConceptsSickle cell diseaseClinical trialsEnd-organ damagePatient-reported outcomesSevere pain episodesPatient-centered approachPRO toolsPain episodesSecondary outcomesChronic diseasesImproved outcomesCell diseasePRO measuresClinical practiceDisease severityClinical useDiseaseOutcomesAbnormal polymerizationTrialsSeverityHemoglobinAltered Hemodynamics and End-Organ Damage in Heart Failure
Verbrugge FH, Guazzi M, Testani JM, Borlaug BA. Altered Hemodynamics and End-Organ Damage in Heart Failure. Circulation 2020, 142: 998-1012. PMID: 32897746, PMCID: PMC7482031, DOI: 10.1161/circulationaha.119.045409.Peer-Reviewed Original ResearchConceptsHeart failureHemodynamic derangementsHemodynamic perturbationsElevated cardiac filling pressuresReduced cardiac outputCardiac filling pressuresEnd-organ damagePulmonary vascular diseaseHeart failure phenotypeMultiple organ systemsCapillary stress failureDevelopment of abnormalitiesCardiogenic shockHemodynamic abnormalitiesRenal functionEjection fractionClinical outcomesPulmonary congestionVenous capacityCardiac outputPericardial constraintVascular diseaseChronic diseasesFilling pressureVentilatory controlLeukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits
Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Review Of Hematology 2020, 13: 489-499. PMID: 32248712, DOI: 10.1080/17474086.2020.1751609.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsWhite blood cell countAcute myeloid leukemiaTumor lysis syndromeMyeloid leukemiaPeripheral white blood cell countEvidence-based clinical guidelinesTotal white blood cell countEnd-organ damageRelevant patient outcomesWide practice variationBlood cell countPeripheral myeloblastsLysis syndromeIntravascular coagulationSurvival benefitOrgan damageClinical guidelinesPatient outcomesPractice variationLeukocytapheresisHigh riskCytoreductive strategyCell countHyperleukocytosisCells/L
2019
The Relationship between Mental Health, Educational Attainment, Employment Outcomes, and Pain in Sickle Cell Disease
Harris K, Varughese T, Bauer A, Howdeshell S, Calhoun C, Abel R, King A. The Relationship between Mental Health, Educational Attainment, Employment Outcomes, and Pain in Sickle Cell Disease. Blood 2019, 134: 419. DOI: 10.1182/blood-2019-129874.Peer-Reviewed Original ResearchLength of painSickle cell diseaseSeverity of painHistory of depressionSevere painPain outcomesAnnual household incomePain crisisPain frequencyCell diseaseSocioeconomic statusMultivariate analysisSeverity of SCDSignificant associationEmployment statusMental healthHigher pain frequencyHospital admission frequencyEnd-organ damageFrequency of painVariety of complicationsPatients' educational attainmentCross-sectional studyOnly significant associationPatient survey dataLong-term Follow-up of Severe Eosinophilic Hepatitis: A Rare Presentation of Hypereosinophilic Syndrome
Awadie H, Khoury J, Zohar Y, Yaccob A, Veitsman E, Saadi T. Long-term Follow-up of Severe Eosinophilic Hepatitis: A Rare Presentation of Hypereosinophilic Syndrome. Rambam Maimonides Medical Journal 2019, 10: e0020. PMID: 31335311, PMCID: PMC6649775, DOI: 10.5041/rmmj.10373.Peer-Reviewed Original ResearchHypereosinophilic syndromeIdiopathic hypereosinophilic syndromeLiver involvementLong-term follow-upIsolated liver involvementSolid organ involvementRare systemic diseaseEnd-organ damageIntensive immunosuppressive treatmentAdvanced liver failureHigher eosinophil countsEosinophilic hepatitisImmunosuppressive treatmentChronic hepatitisLiver dysfunctionOrgan involvementLiver biopsyLiver failureEosinophil countOrgan damageRare presentationSystemic diseaseFollow-upAppropriate treatmentLow dose
2018
Chapter 4 Common Significant Non-ABO Antibodies and Blood Group Antigen Alloimmunization
Baine I, Hendrickson J, Tormey C. Chapter 4 Common Significant Non-ABO Antibodies and Blood Group Antigen Alloimmunization. 2018, 25-39. DOI: 10.1016/b978-0-323-54458-0.00004-0.ChaptersNon-ABO antibodiesBlood group antibodiesGroup antibodiesCompatible RBC unitsEnd-organ damageHemolytic transfusion reactionsSetting of pregnancyCommon adverse outcomeFormation of alloantibodiesSickle cell diseaseRBC alloimmunizationPregnant patientsOrgan damageMyelodysplastic syndromePregnant womenAdverse outcomesGeneral patientsTransfusion reactionsHemolytic diseaseCell diseaseHigh riskRed blood cell surfaceImmunologic conceptsClinical practiceAlloimmunization
2017
Lupus and proliferative nephritis are PAD4 independent in murine models
Gordon RA, Herter JM, Rosetti F, Campbell AM, Nishi H, Kashgarian M, Bastacky SI, Marinov A, Nickerson KM, Mayadas TN, Shlomchik MJ. Lupus and proliferative nephritis are PAD4 independent in murine models. JCI Insight 2017, 2: e92926. PMID: 28515361, PMCID: PMC5436537, DOI: 10.1172/jci.insight.92926.Peer-Reviewed Original ResearchSystemic lupus erythematosusNeutrophil extracellular trapsProliferative nephritisMurine modelContribution of NETsInhibition of NETsAnti-glomerular basement membrane modelEnd-organ damageLoss of toleranceRecent reportsLupus erythematosusOrgan injuryImmune activationExtracellular trapsPeptidyl arginine deiminasePharmacological approachesBasement membrane modelDistal mediatorsNADPH oxidase complexPharmacological inhibitionNephritisInducible modelLupusNET formationType IV
2016
Implementation of an Educational Intervention to Optimize Self-Management and Transition Readiness in Adolescents with Sickle Cell Disease
Calhoun C, Abel R, Pham H, Thompson S, King A. Implementation of an Educational Intervention to Optimize Self-Management and Transition Readiness in Adolescents with Sickle Cell Disease. Blood 2016, 128: 3536. DOI: 10.1182/blood.v128.22.3536.3536.Peer-Reviewed Original ResearchSickle cell diseaseEducational handoutAdult careCell diseaseTransition readinessSilent cerebral infarctsEnd-organ damageSubsequent clinic visitsEducational interventionHistory of strokeMajority of patientsPediatric hematology clinicYear oldsFormal transition programAge group 13Institutional review boardUniversity Institutional Review BoardCerebral infarctsChart abstractionClinic visitsStandard careIndependent livingHematology clinicMedical managementOrgan damageNocturnal Non-dipping Blood Pressure Profile in Black Normotensives Is Associated with Cardiac Target Organ Damage.
Mezue K, Isiguzo G, Madu C, Nwuruku G, Rangaswami J, Baugh D, Madu E. Nocturnal Non-dipping Blood Pressure Profile in Black Normotensives Is Associated with Cardiac Target Organ Damage. Ethnicity & Disease 2016, 26: 279-84. PMID: 27440966, PMCID: PMC4948793, DOI: 10.18865/ed.26.3.279.Peer-Reviewed Original ResearchConceptsCardiac target organ damageTarget organ damageNon-DippersBlood pressure profileNocturnal blood pressureOrgan damageBlood pressureBlack normotensivesNon-dipping of blood pressureMass indexCardiovascular riskLeft atrial volume indexLeft ventricular mass indexCardiovascular end-organ damageIncreased relative wall thicknessAtrial volume indexAmbulatory blood pressure patternsNon-dipper groupVentricular mass indexNocturnal non-dippingNon-dipping profileNon-dipping patternPredictor of cardiovascular riskEnd-organ damageNon-dipping blood pressure profilePrimary Hyperparathyroidism in Children and Adolescents
Lo H, Tebben P. Primary Hyperparathyroidism in Children and Adolescents. 2016, 117-128. DOI: 10.1007/978-3-319-25880-5_14.ChaptersPrimary hyperparathyroidismMultiple-gland diseaseSporadic primary hyperparathyroidismDegree of hypercalcemiaAssociated with greater morbidityEnd-organ damageTime of diagnosisHigh-volume surgeonsParathyroid hormone concentrationsTarget organ sensitivityPediatric patientsRare conditionYounger patientsGreater morbidityEndocrine surgeryEndocrine disordersFamilial diseaseAffected organsHormone concentrationsHyperparathyroidismSurgeryPatientsDiseaseAdultsHypercalciuriaThe Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions.
Hamoudeh E, Zeidan AM, Barbarotta L, Rosano N. The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions. Current Diabetes Reviews 2016, 12: 231-9. PMID: 26008639, DOI: 10.2174/1573399811666150526151241.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDiabetes mellitusMyelodysplastic syndromeDiabetic patientsManagement of MDSOutcomes of patientsEnd-organ damageRisk of progressionRisk of complicationsCommon hematologic malignancyIntensive therapeutic interventionMultiple epidemiologic studiesAcute myeloid leukemiaLow blood countsDiabetic controlAdjunct drugsGlucose controlBlood countImportant unmetInsulin resistanceDysplastic changesHematologic malignanciesRisk factorsMyeloid leukemiaEpidemiologic studiesTherapeutic interventions
2015
The Role of 18F Fluorodeoxyglucose Positron Emission Tomography Scanning in the Diagnosis and Management of Systemic Vasculitis
Danve A, O'Dell J. The Role of 18F Fluorodeoxyglucose Positron Emission Tomography Scanning in the Diagnosis and Management of Systemic Vasculitis. International Journal Of Rheumatic Diseases 2015, 18: 714-724. PMID: 26177990, DOI: 10.1111/1756-185x.12713.Peer-Reviewed Original ResearchConceptsGiant cell arteritisPositron emission tomography scanningFDG-PETSystemic vasculitisTakayasu arteritisMagnetic resonance imagingEarly diagnosisFluorodeoxyglucose positron emission tomography scanningCranial giant cell arteritisTomography scanningBlood vesselsInvolved blood vesselsEnd-organ damageLarge vessel vasculitidesPrimary systemic vasculitisSmall vessel vasculitisNon-specific symptomsActive inflammatory cellsStandard imaging testPrediction of relapseDisease activityActive inflammationCell arteritisVessel vasculitisOrgan damageComplement C1q-induced activation of β-catenin signalling causes hypertensive arterial remodelling
Sumida T, Naito AT, Nomura S, Nakagawa A, Higo T, Hashimoto A, Okada K, Sakai T, Ito M, Yamaguchi T, Oka T, Akazawa H, Lee JK, Minamino T, Offermanns S, Noda T, Botto M, Kobayashi Y, Morita H, Manabe I, Nagai T, Shiojima I, Komuro I. Complement C1q-induced activation of β-catenin signalling causes hypertensive arterial remodelling. Nature Communications 2015, 6: 6241. PMID: 25716000, PMCID: PMC4351572, DOI: 10.1038/ncomms7241.Peer-Reviewed Original ResearchConceptsVascular smooth muscle cellsProliferation of VSMCsArterial remodellingΒ-catenin signalingΒ-cateninComplement C1qBlood pressure elevationEnd-organ damageNovel therapeutic targetSmooth muscle cellsMacrophage depletionImmune cellsPrecise molecular mechanismsTherapeutic targetStructural remodellingMuscle cellsRemodellingHypertensionArteriosclerosisComplement C1ActivationC1qMolecular mechanismsSignalingGene deletion
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply